CHF10067 / Chiesi - LARVOL DELTA

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD). (clinicaltrials.gov) - P1 | N=52 | Completed | Sponsor: Chiesi Farmaceutici S.p.A. | N=24 ➔ 52

Enrollment change • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Safety, Tolerability, and Pharmacokinetics of CHF10067 in Subjects With Idiopathic Pulmonary Fibrosis: A Phase Ib Study (ATS 2025) - P1 | "This abstract is funded by: Chiesi Farmaceutici S.p.A., Parma, Italy RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with limited treatment options. Zampilimab demonstrated a favorable safety and tolerability profile in subjects with IPF at all doses up to 3000 mg. These findings support further clinical development of zampilimab for the treatment of IPF."

Clinical • Late-breaking abstract • P1 data • PK/PD data • Cardiovascular • Fatigue • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Influenza • Pain • Pulmonary Disease • Respiratory Diseases • TGM2

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Chiesi Farmaceutici S.p.A. | Active, not recruiting ➔ Completed

Trial completion • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • TGM2

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Chiesi Farmaceutici S.p.A. | Recruiting ➔ Active, not recruiting

Enrollment closed • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • TGM2

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Chiesi Farmaceutici S.p.A. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2023 ➔ May 2024 | Initiation date: Sep 2022 ➔ Jan 2023 | Trial primary completion date: Jun 2023 ➔ May 2024

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Chiesi Farmaceutici S.p.A.

New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases